Key result
Obesity with impaired glucose tolerance or T2D was associated with significantly higher serum IL-1RA levels compared to normal weight (1265 vs 440 pg/mL; P<0.001), which decreased after RYGB.
Why the study?
To compare circulating concentrations and visceral adipose tissue expression of IL-1RA across body weight and glycemic categories, and evaluate how body fat changes affect IL-1RA levels.
Does weight loss via Roux-en-Y gastric bypass reduce serum IL-1RA concentrations in patients with obesity?
Population
156 volunteers categorized as NW, OB-NG, or OB-IGT&T2D
Comparison
NW vs OB-NG vs OB-IGT&T2D, and before vs after weight gain or weight loss
Design
Observational cohort study
Loading...
May serve as biomarker of metabolic inflammation responsive to weight loss; leaves open therapeutic targeting in T2D.
Observational (n=156)
Does weight loss via Roux-en-Y gastric bypass reduce serum IL-1RA concentrations in patients with obesity?
p-value: p=<0.001
Serum IL-1RA is elevated in obesity and T2D, correlating with adipose tissue dysfunction, and is significantly reduced following substantial weight loss via bariatric surgery.
A 2022 study conducted an observational in Obesity and Type 2 Diabetes (n=156). Obesity and impaired glucose tolerance or T2D vs. Normal weight was evaluated on Serum concentrations of IL-1RA (p=<0.001). Obesity with impaired glucose tolerance or T2D was associated with significantly higher serum IL-1RA levels compared to normal weight (1265 vs 440 pg/mL; P<0.001), which decreased after RYGB.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: